IO-202 is a monoclonal antibody that targets leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), which can suppress immunity in solid tumours. Image Credit: crystal light / Shutterstock.
IO-202phan drug designations allow for an extended market exclusiUS FDAf seven years in the US and developmental incentives such as an exemption of FDA application fees and tax credits for qualified clinical testing. The fast acute myeloid leukaemia (AML)lier intFDActions with the FDA for the pursuit of accelerated approval. The status also opens chances of rolling reviews.
IO-202 is a monoclonal antibody that targets leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), which can suppress immunity in soFDA tumours. It also mediates the T-cell suppression and infiltration of AML cells.FDA
A second Phase I trial (NCT05309187) investigating IO-202 in combination with a PD-1 immune checkpoint inhibitor, MSD’s Keytruda (pembrolizumab) is also currently underway. The study enrolled approximately 200 patients with advanced solid tumours and is expected to be completed in April.
United Therapeuticses havFDAeen identified as Liquidianovation area for cancer therapy by GlobalData, with multiple companies investing to develop antibody therapies for various indications. In December 2023, AbbVie partnered with BigHat Biosciences to identify and develop antibody therapies in oncology and neuroscience indications.
GlobalData is the parent company of Pharmaceutical Technology.